Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent Inc (NYSE: CTLT) delivers essential pharmaceutical development solutions and manufacturing services for global healthcare partners. This dedicated news hub provides investors and industry professionals with timely updates on Catalent's operational milestones, strategic initiatives, and regulatory developments.
Access authoritative reporting on material events including clinical manufacturing advancements, drug delivery innovations, and global supply chain expansions. Our curated collection features earnings disclosures, partnership announcements, and facility updates directly impacting Catalent's market position.
Key focus areas include bioavailability enhancement technologies, commercial packaging solutions, and biologics manufacturing capabilities. Monitor critical updates through verified press releases and objective analysis of Catalent's role in accelerating therapeutic development timelines.
Bookmark this page for streamlined tracking of CTLT's progress in formulation science, regulatory submissions, and capacity investments across its global manufacturing network.
Catalent, Inc. (NYSE: CTLT) announced a business update reflecting challenges during the third fiscal quarter ending March 31, 2023. The company expects higher costs and productivity issues at three facilities, impacting financial results. Specifically, the Harmans, Maryland facility faced operational setbacks related to a new ERP system deployment, affecting revenue generation. Similar issues were reported at facilities in Bloomington, Indiana and Brussels, Belgium, which may persist into the next quarter. In leadership changes, Ricky Hopson is appointed Interim Chief Financial Officer as of April 14, 2023. The company anticipates releasing Q3 fiscal year results on May 9, 2023, which may clarify the financial impact of these challenges.
Catalent, Inc. (NYSE: CTLT) has announced participation in two major investor conferences in March 2023. The first event is the Barclays Global Healthcare Conference on March 14 at 10:45 a.m. ET, followed by the KeyBanc Life Sciences & MedTech Investor Forum on March 21 at 12:00 p.m. ET. Interested investors can access a live webcast of both presentations through the Catalent investor relations page. Catalent, headquartered in Somerset, New Jersey, generated nearly $5 billion in revenue for the 2022 fiscal year and is a leader in the development and supply of pharmaceutical and biotech treatments.
FAQ
What is the current stock price of Catalent (CTLT)?
What is the market cap of Catalent (CTLT)?
